Common heart drug taken by millions found useless, possibly risky | AI News Digest
A groundbreaking study, the REBOOT Trial, has found that beta blockers, long prescribed for patients after heart attacks, offer no clinical benefit for those with preserved heart function. This research, led by Dr. Valentin Fuster, challenges a 40-year treatment standard and suggests that beta blockers may even pose risks, particularly for women. The trial involved over 8,500 patients and revealed no significant differences in health outcomes between those treated with beta blockers and those who were not. The findings are expected to reshape international clinical guidelines and improve patient care by reducing unnecessary medication and associated side effects. This significant advancement in heart attack treatment could enhance the quality of life for many patients.
